Cannabis for PTSD

Home » Our Reseach » Cannabis for PTSD

Cannabis for Symptoms of PTSD in U.S. Veterans

MAPS has received regulatory approval to conduct a study of smoked cannabis for symptoms of PTSD in veterans of war. The study evaluated safety and efficacy of four different potencies of cannabis.

The WeCan Study is an effort of MAPS to collect information about the efficacy of cannabis-based treatments for PTSD.

The WeCan Study is a Phase 2 clinical trial to test safety and efficacy of four different concentrations of cannabis in people with PTSD. This study explores whether smoked cannabis can help reduce PTSD symptoms in U.S. veterans with chronic, treatment-resistant PTSD.

Phase 2 Clinical Trial

Placebo-controlled, triple-blind, randomized crossover pilot study of the safety and efficacy of four different potencies of smoked cannabis in 76 Veterans with chronic, treatment-resistant PTSD. Participants were U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after trying either medication or psychotherapy. Enrollment for this study is complete.

Primary endpoint – Change in CAPS-5 Total Severity Score from baseline [Time Frame: Baseline, 3 weeks after randomization].

To learn more about using cannabis to treat PTSD, visit

Are you a U.S. Military Veteran?
Have you experienced traumatic stress?

MAPS Public Benefit Corporation

Our Mission
Who We Are
Contact Us
Privacy Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!